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A B S T R A C T
Purpose
We conducted a retrospective analysis to assess the safety proﬁle of nivolumab monotherapy in
patients with advanced melanoma and describe the management of adverse events (AEs) using
established safety guidelines.
Patients and Methods
Safety data were pooled from four studies, including two phase III trials, with patients who received
nivolumab 3 mg/kg once every 2 weeks. We evaluated rate of treatment-related AEs, time to onset
and resolution of select AEs (those with potential immunologic etiology), and impact of select AEs
and suppressive immune-modulating agents (IMs) on antitumor efﬁcacy.
Results
Among 576 patients, 71% (95% CI, 67% to 75%) experienced any-grade treatment-related AEs (most
commonly fatigue [25%], pruritus [17%], diarrhea [13%], and rash [13%]), and 10% (95%CI, 8% to 13%)
experienced grade 3 to 4 treatment-related AEs. No drug-related deaths were reported. Select AEs
(occurring in 49% of patients) were most frequently skin related, GI, endocrine, and hepatic; grade 3 to
4 select AEs occurred in 4%of patients.Median time to onset of select AEs ranged from5weeks for skin
to 15weeks for renal AEs. Approximately 24%of patients received systemic IMs tomanage select AEs,
which in most cases resolved. Adjusting for number of doses, objective response rate (ORR) was
signiﬁcantly higher in patientswhoexperienced treatment-related select AEs of any grade comparedwith
thosewho did not. ORRswere similar in patientswho did and patientswho did not receive systemic IMs.
Conclusion
Treatment-related AEs with nivolumab monotherapy were primarily low grade, and most resolved
with established safety guidelines. Use of IMs did not affect ORR, although treatment-related select
AEs of any grade were associated with higher ORR, but no progression-free survival beneﬁt.
J Clin Oncol 34. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Nivolumab is a fully human immunoglobulin G4
programmed death-1 (PD-1) checkpoint in-
hibitor antibody that selectively blocks the in-
teraction of the PD-1 receptor with its known
ligands, programmed death ligand-1 (PD-L1)
and programmed death ligand-2 (PD-L2), dis-
rupting signals that downmodulate T-cell activa-
tion and proliferation.1 Nivolumab has signiﬁcant
clinical activity either as monotherapy or in com-
bination with ipilimumab in several tumor types,
including non–small-cell lung cancer, mela-
noma, and renal cell carcinoma.2-8 A majority of
responses have been durable and persisted after
treatment discontinuation in patients who
stopped therapy for reasons other than disease
progression.4,9
CheckMate 066, a recently completed phase
III trial of nivolumab monotherapy, showed sig-
niﬁcant improvement in progression-free survival
(PFS) and overall survival (OS) and a manageable
safety proﬁle compared with chemotherapy in
patients with previously untreated, advanced mel-
anoma.10 In another phase III study, CheckMate
037, nivolumab induced a higher objective response
rate (ORR) compared with investigator’s choice of
chemotherapy in patients with advanced melanoma
who experienced progression after prior ipilimu-
mab therapy or ipilimumab plus a BRAF inhibitor
in cases of BRAF mutation–positive disease.7
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In nivolumab studies to date, treatment-related adverse events
(AEs) have included dermatologic, GI, endocrine, hepatic, renal,
and pulmonary toxicities. Most AEs have been low grade and
managed successfully with supportive care. Most grade 3 to 4 AEs
have resolved with nivolumab dose delay or permanent discon-
tinuation, with or without administration of systemic cortico-
steroids or other suppressive immune-modulating agents (IMs).
To better characterize the safety proﬁle of immune checkpoint
inhibitors including nivolumab, a classiﬁcation of the most
common and clinically signiﬁcant immune-related (ie, select) AEs
associated with these drugs was developed. Select AEs were
classiﬁed into organ categories, for which speciﬁc guidelines
were developed.7,10 These guidelines or algorithms include the
use of IMs, particularly systemic corticosteroids, to manage AEs
with a potential immune-related etiology.11 To further describe
the safety proﬁle of nivolumab in advanced melanoma and
examine outcomes of select AE management on the basis of the
use of the proposed safety management guidelines, we con-
ducted a pooled data analysis for patients receiving nivolumab at
3 mg/kg every 2 weeks, across multiple recent clinical trials.
PATIENTS AND METHODS
Patients
All patients in this analysis received at least one dose of nivolumab at
3 mg/kg once every 2 weeks in one of the following clinical trials:
• Phase I dose-ranging study in previously treated, advanced solid
tumors (CA209-003; clinical trial information: NCT00730639; n = 17
[patients with melanoma in the 3-mg/kg cohort])6,9
• Phase I exploratory biomarker study in advancedmelanoma (CA209-
038; clinical trial information: NCT01621490; n = 85)
• Phase III study of nivolumab versus chemotherapy in advanced
melanoma after progression with ipilimumab or ipilimumab plus
a BRAF inhibitor in cases of BRAF V600 mutation–positive disease
(CheckMate 037; clinical trial information: NCT01721746; n = 268)7
• Phase III study of nivolumab versus dacarbazine in patients with
previously untreated melanoma without a BRAF mutation (Check-
Mate 066; clinical trial information: NCT01721772; n= 206)10
Patients were treated until disease progression or unacceptable
toxicity in the phase III trials or for up to 2 years in the phase I trials.
Only patients in studies CA209-038 and CheckMate 037 had received
prior ipilimumab therapy (n = 44) and (n 268), respectively, with
a minimum time between the last dose of ipilimumab and the ﬁrst dose
of nivolumab of 6 weeks.
Efficacy and Safety Assessments
Safety evaluations included assessment of treatment-related AEs,
treatment-related select AEs, time to onset and resolution of select AEs,
and use of IMs to manage select AEs. Select AEs were deﬁned as having
a potential immunologic basis that required more frequent monitoring
and potential intervention with immune suppression and/or endocrine
replacement therapy. AEs were coded using the Medical Dictionary for
Regulatory Activities version 16.1 for CheckMate 037 and CA209-038 and
version 17.0 for CA209-003 and CheckMate 066.
AEs were graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events version 3.0 for CA209-003 and
version 4.0 for all other studies. Data on time to onset and resolution of
treatment-related select AEs and on IM use were available from the two
phase III trials: CheckMate 037 and CheckMate 066 (n = 474). Time to
resolution of a select AE was deﬁned as the longest time from onset to
complete resolution or improvement to the baseline grade, among all
clustered select AEs belonging to a select AE category experienced by
the patient.
An exploratory analysis evaluated the relationship between the de-
velopment of select AEs and ORR or PFS, with AEs occurring before the
date of event for PFS included in these analyses. To evaluate the potential
impact of AE management on the efﬁcacy of nivolumab, ORRs were
Table 1. All AEs, Treatment-Related AEs, and Treatment-Related Select AEs*
by Organ Category
AE Term†
Patients With AE (%)‡
(N = 576)
Any Grade Grade 3 to 4
Any AE, regardless of attribution 95.3 34.9§
Any treatment-related AE in $ 5% of patients 71.0 9.9k
Fatigue 24.8 0.3
Pruritus 17.2 0.2
Diarrhea 12.7 0.5
Rash 12.7 0.3
Nausea 12.0 0
Vitiligo 7.8 0
Arthralgia 6.8 0
Asthenia 6.8 0
Constipation 5.6 0
Hypothyroidism 5.2 0
Decreased appetite 5.2 0
Any treatment-related AE leading to
discontinuation of study drug
3.0 2.1
Treatment-related select AEs 49.0 3.6
Skin 34.0 0.7
Pruritus 17.2 0.2
Rash 12.7 0.3
Vitiligo 7.8 NA
Rash maculopapular 4.5 0.2
GI 13.4 1.2
Diarrhea 12.7 0.5
Colitis 1.0 0.7
Endocrine 7.8 0.3
Hypothyroidism 4.2 0
Hyperthyroidism 2.1 0.2
Hypophysitis 0.2 0.2
Hepatic 4.2 1.0
AST increased 2.8 0.3
ALT increased 1.9 0.7
g-glutamyltransferase increased 0.2 0.2
Hepatitis 0.2 0.2
Liver function test abnormal 0.2 0.2
Pulmonary 1.9 0
Pneumonitis 1.7 0
Renal 1.4 0.3
Blood creatinine increased 0.5 0
Renal failure acute 0.2 0.2
Tubulointerstitial nephritis 0.2 0.2
Abbreviations: AE, adverse event; NA, not applicable.
*Select AEs are deﬁned as AEs with a potential immunologic cause that need
frequent monitoring and potential intervention with immune suppression and/or
endocrine treatment. All grade 3 to 4 select AEs are shown.
†Terms are per Medical Dictionary for Regulatory Activities version 16.1 for
CA209-038 and CheckMate 037 and version 17.0 for CA209-003 and CheckMate
066.
‡Individual patients may have had more than one event.
§In addition, rate of any grade 5 event (none were attributed to treatment) was
5.2%.
kGrade 3 to 4 events that were not select AEs included general disorders (eg,
fatigue, peripheral edema), vomiting, abdominal pain, musculoskeletal and
connective tissue disorders, certain laboratory investigations, metabolism
and nutrition disorders (eg, hyperglycemia), nervous system disorders, blood
and lymphatic system disorders, infections, infusion-related reactions, vascular
disorders, cardiac disorders, and eye disorders.
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compared in patients who received systemic IMs and in those who did not.
Systemic IM use was deﬁned as the use of systemic corticosteroids on the
basis of detailed information reported only in the two phase III trials.
Tumor assessments were performed using Response Evaluation Criteria in
Solid Tumors (RECIST) version 1.0 (CA209-003) or version 1.1 (CA209-
038, CheckMate 037, and CheckMate 066). Patients evaluable for response
had a baseline tumor assessment, ﬁrst treatment evaluation scan 9 to
12 weeks after random assignment, and conﬁrmatory scan at least
4 weeks after the ﬁrst documented response. There was no apparent
heterogeneity between studies in rate of AEs, and we did not control for
other end points or study-speciﬁc effects.
Statistical Analysis
ORRswith 95%CIs were estimated using the Clopper-Pearsonmethod.
Medians for PFS were calculated using the Kaplan-Meier method. Multi-
variate analyses were conducted when evaluating relationships between select
AEs and ORRs, to adjust for imbalances across patients in number of
nivolumab doses (which relates to time receiving therapy), baseline
lactate dehydrogenase (LDH), and tumor PD-L1 expression. Addition-
ally, a landmark analysis at 12 weeks was performed for PFS, including
only patients alive at follow-up starting at 12 weeks after the ﬁrst
treatment (n = 309). The PFS analysis was performed on the basis of this
landmark assessment of immune-related AEs that developed within the
ﬁrst 12 weeks, comparing survival curves for patients with no select AEs
versus those with one to two AEs and three or more AES as well as all
patients versus those with all-grade AEs and grade 3 to 4 AEs, using data
starting at 12 weeks post-treatment. The Cochran-Mantel-Haenszel
method of weighting was used to determine odds ratios and P values for
ORRs. All analyses were conducted using SAS software (version 9; SAS
Institute, Cary, NC).
RESULTS
A total of 576 nivolumab-treated patients were included in this
analysis. Baseline characteristics are shown in Appendix Table A1
(online only). Median age was 61 years; 43% of patients had
elevated serum LDH levels, and 12% had treated brain metastases.
A total of 312 patients (54%) had received prior ipilimumab
therapy. Median treatment duration was 3.7 months, and patients
received a median of nine doses of nivolumab. Median follow-up
was 7.2 months (range, 0.3 to 62.5 months). Patients who ex-
perienced treatment-related select AEs of any grade received
a greater median number of doses of nivolumab (13 v seven) and
had longer median treatment duration (6.0 v 2.8 months; Ap-
pendix Table A2, online only).
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Fig 1. Time to onset and resolution of
treatment-related select adverse events
(AEs) of any grade, with or without use of
immune-modulating agents. Circles rep-
resent medians, and bars indicate ranges
(values shown above bars). The treatment
population included those in phase III trials
(N = 474). (A) For time to onset, number
and percent indicate AE incidence. (B) For
time to resolution, number and percent
indicate patients’ whose AE resolved. The
symbols “+” in ranges and “¤” on bars
indicate censored values.
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Pooled Safety Analysis
At the time of analysis, 149 patients (26%) had died. The most
commonly reported cause of death was disease progression (140 of
149; 94%). Other reported causes of death were acute myocardial
infarction, cardiopulmonary arrest, heart failure, hypoxia, sepsis
with multiorgan failure, subarachnoid bleeding (suspected cause),
and probable pulmonary embolism; in two patient cases, the cause
of death was unknown. No deaths were attributed to nivolumab
toxicity.
Treatment-related AEs of any grade occurred in 71% of pa-
tients (95% CI, 67% to 75%). The most frequently reported events
were fatigue (25%), pruritus (17%), diarrhea (13%), and rash
(13%), as listed in Table 1 and Appendix Table A3 (online only).
AEs regardless of attribution are listed in Appendix Table A4,
(online only). Grade 3 to 4 treatment-related AEs were reported
in 57 patients (10%; 95% CI, 8% to 13%). Of note, grade 3 to
4 neurologic AEs (all grade 3) were reported in ﬁve patients
(1%): dizziness (resolved); autoimmune neuropathy (resolved
in 16 weeks); central demyelination (ongoing for . 3 weeks
before death resulting from disease progression); Guillain-Barre´
syndrome (unresolved for . 16 weeks at time of database lock);
and involuntary muscle contractions (resolved).
Treatment-related AEs leading to discontinuation were re-
ported in 17 patients (3%), with the most common being colitis,
increased alanine aminotransferase, increased lipase, and pneu-
monitis (two patients [0.3%] each). There were no instances of GI
perforation.
The rates of any-grade and grade 3 to 4 treatment-related AEs
in patients who had received prior ipilimumab were 69% and 8%,
respectively, similar to the rates in the overall study population.
Likewise, AE rates in the overall population were consistent with
those in patients $ 65 years of age (any grade, 73%; grade 3 to 4,
15%);$ 75 years of age (any grade, 72%; grade 3 to 4, 18%); with
brain metastases (any grade, 61%; grade 3 to 4, 8%); with M1c
stage disease (any grade, 71%; grade 3 to 4, 9%); with PD-L1
expression greater than 5% (any grade, 80%; grade 3 to 4, 14%);
and with elevated LDH (any grade, 67%; grade 3 to 4, 8%).
Treatment-related select AEs occurred in 49% of patients and
were most commonly observed in the skin (34%) and GI tract
(13%); grade 3 to 4 treatment-related select AEs were reported in
4% of patients (Table 1). Median time to onset for treatment-
related select AEs of any grade ranged from 5.0 weeks for skin AEs
to 15.1 weeks for renal AEs (Fig 1A). Select AEs generally resolved
within several weeks, with the shortest time to resolution for GI
events (Fig 1B). Endocrine select AEs had the longest median time
to resolution, because some events, although clinically resolved and
medically controlled, were not considered resolved while there was
a continuing need for hormone replacement therapy. The kinetics of
onset and resolution of the most common treatment-related select
AEs are shown in Figure 2, which demonstrates the median times to
onset and resolution of select AEs of all grades by organ category.
Among 282 patients who experienced new treatment-related select
AEs, 85% did so within the ﬁrst 16 weeks of treatment (Fig 3).
Impact of AEs on Response Rates and PFS
In all patients receiving nivolumab monotherapy (N = 576),
the ORR was 31.4%, and median PFS was 4.7 months (95% CI, 3.4
to 5.6). In a multivariable analysis adjusting for differences in
number of nivolumab doses received, baseline LDH, and tumor
PD-L1 expression, ORR was signiﬁcantly better in patients who
experienced treatment-related select AEs of any grade compared
with those who did not, with greater beneﬁt in patients who re-
ported three or more or one to two treatment-related select AEs,
compared with those with none (Table 2). In contrast, there was no
signiﬁcant difference in ORR on the basis of the occurrence of
grade 3 to 4 treatment-related select AEs (Table 2). Exclusion of
patients who experienced progression before 12 weeks in a land-
mark PFS analysis revealed no difference in PFS between patients
without AEs and those with one to two AEs or between those with
any-grade AE and all patients (Appendix Fig A1, online only).
Use of IMs to Manage Select AEs
A total of 114 of 474 (24%) of patients in the two phase III
trials received systemic corticosteroids to manage treatment-
related AEs of any kind. In addition, 76 (16%) were adminis-
tered topical corticosteroids to manage skin-related AEs, and ﬁve
(1%) received inhaled corticosteroids (Appendix Table A5, online
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Fig 2. Kinetics of onset and resolution of (A) most common ($ 10%) and (B) less
common (, 10%) treatment-related select adverse events (AEs) of any grade. The
beginning and end of each curve represent the median time to onset and median
time to resolution, respectively. The peak of each curve shows the proportion of
patients who developed that AE, and the tail represents the proportion of patients
whose AE did not resolve.
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only). Only three patients (0.6%) received a secondary immu-
nosuppressive agent: inﬂiximab for grade 3 arthritis and grade 4
lipase increase in CheckMate 037, (n = 2); and mycophenolic acid
for grade 3 hepatitis in CheckMate 066 after subsequently re-
ceiving ipilimumab off study, (n = 1).
When examining treatment-related select AEs for which IMs
were initiated, a majority of events (58%) resolved. Median time to
resolution of treatment-related select AEs of any grade with IMs
ranged from 3.3 weeks for hepatic AEs to 28.6 weeks for skin AEs
(Fig 4). Among 13 patients with grade 3 to 4 treatment-related
select AEs who received IMs, all patients experienced resolution
except one with skin AE (rash), who was treated with systemic
corticosteroids and experienced improvement to a grade 1 event.
Impact of Systemic IMs on Response Rates
A total of 114 patients who received systemic IMs to manage
treatment-related AEs and 462 who did not receive IMs were
evaluable for tumor response. There was no signiﬁcant difference
in ORRs between patients who did versus those who did not
receive systemic IMs (Table 2). Median duration of response was
not reached (95% CI, 9.3 to not reached) in patients receiving
IMs and was 22.0 months (95% CI, 22.0 to not reached) in those
not receiving IMs.
DISCUSSION
To our knowledge, this report pooling data from four melanoma
trials is the largest and most comprehensive analysis to date of the
safety proﬁle of anti–PD-1 monotherapy. We found that ap-
proximately 50% of patients experienced AEs with a potential
immunologic etiology (select AEs). Select AEs were typically mild
to moderate in intensity, being severe (grade 3 to 4) in less than 4%
of patients. They most commonly occurred in the skin, GI tract,
and endocrine organs. The types of select AEs observed with
nivolumab therapy were similar to those previously observed with
another immune checkpoint inhibitor, ipilimumab (anti–cytotoxic
T-cell lymphocyte-4), in advanced melanoma.12 However, their
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Fig 3. Occurrence of new treatment-
related select adverse events of any grade
over time (n = 282 of 576).
Table 2. Impact of Treatment-Related Select AEs and IM Use on Response to Nivolumab Therapy
All Patients (N = 576)
Any-Grade Treatment-Related Select AEs*
Grade 3 to 4 Treatment-
Related Select AEs
Patients Receiving
Systemic IM
Any
(n = 255)
None
(n = 321)
1-2
(n = 242)
$ 3
(n = 13)
Yes
(n = 18)
No
(n = 558)
Yes
(n = 114)
No
(n = 462)
ORR, No. of
patients (%)
181 (31.4) 124 (48.6) 57 (17.8) 113 (46.7) 11 (84.6) 5 (27.8) 176 (31.5) 34 (29.8) 147 (31.8)
95% CI 27.6 to 35.4 42.3 to 54.9 13.7 to 22.4 40.3 to 53.2 54.6 to 98.1 9.7 to 53.5 27.7 to 35.6 21.6 to 39.1 27.6 to 36.3
P , .001 , .0001† , .001† 1.00 .736
Abbreviations: AE, adverse event; IM, immune-modulating agent; ORR, objective response rate.
*Data in these columns are for patients with the indicated numbers of any-grade treatment-related select AEs: any AE, no AEs, 1-2 AEs, and $ 3 AEs.
†Versus no treatment-related select AEs.
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prevalence differed, with GI events being less common with
nivolumab than ipilimumab.3
Although treatment-related deaths resulting from pneumonitis
were reported in patients with lung cancer (n = 2) and colorectal
cancer (n = 1) in an early trial of nivolumab monotherapy,6 no
deaths from nivolumab-related pneumonitis have been reported to
date in melanoma trials or in registrational lung trials. Pneumonitis
was infrequent in our analysis, occurring in less than 2% of patients
(grade 1 to 2 only). However, rare and unusual AEs are possible. For
example, grade 3 neurologic toxicities were seen in ﬁve patients in
our analysis. Although a neurologic AE management algorithm by
the manufacturer of nivolumab is available, further information is
required on the optimal approach to these AEs.
Critical to the successful management of select AEs is early
recognition. In general, most select AEs appeared within 1 to
2 months after the start of treatment, with skin AEs being the
earliest (median, 5 weeks), whereas renal select AEs were delayed
(median, 15 weeks). These patterns of onset were similar to those
reported previously with ipilimumab therapy in melanoma.13 In
some cases, patients treated with nivolumab experienced select AEs
many months or more than 1 year after starting treatment, or even
after completing treatment, reinforcing the importance of vigilance
for safety events by the health care team.
Among the 576 patients analyzed here, 312 (54%) had received
ipilimumab in other clinical trials or as standard of care before
nivolumab therapy. Consistent with previous studies,14,15 the in-
cidences of any-grade and grade 3 to 4 treatment-related AEs in the
overall population were similar to those among patients who had
received prior ipilimumab, suggesting that prior immunotherapywith
ipilimumab does not affect the safety proﬁle of nivolumab in ad-
vanced melanoma when administered at least 6 weeks before the ﬁrst
dose of nivolumab. Importantly, the overall incidence of select AEs
with nivolumab monotherapy seemed to be lower than that pre-
viously observed with ipilimumab monotherapy. In a phase III study
that evaluated each of these monotherapies as well as nivolumab
combined with ipilimumab as ﬁrst-line therapy for advanced mel-
anoma, select AEs of any grade and grade 3 to 4, respectively, occurred
in 62% and 8% of patients receiving nivolumab monotherapy and
74% and 19% of patients receiving ipilimumabmonotherapy.3 In our
analysis of nivolumabmonotherapy, any-grade and grade 3 to 4 select
AEs were experienced by 49% and 4% of patients, respectively.
Treatment guidelines for managing AEs with a potential
immunologic etiology were established during the ipilimumab
clinical development program.11,16 Appropriate management of
select AEs is essential to reduce the risk for severe toxicity and
enable nivolumab therapy to be continued where possible, max-
imizing its potential beneﬁts. Using the nivolumab safety man-
agement guidelines, involving the use of IMs (primarily systemic
corticosteroids), all but one grade 3 to 4 select AE resolved.
Although there is a theoretic concern that using immune-
suppressant drugs to mitigate select AEs might interfere with an
anticancer immune response, the results of our analysis suggest that
IMs do not negatively affect the rate or quality of antitumor re-
sponses after nivolumab therapy. Similarly, published ﬁndings with
ipilimumab suggest that corticosteroids do not affect the develop-
ment of antitumor responses (if administered before documentation
of the tumor response) or response duration (if administered after
the patient has achieved a response).17-20
It has been proposed that development of immune-related AEs
may be associated with response to immune checkpoint–blocking
drugs. This phenomenon was ﬁrst described in patients with mel-
anoma receiving ipilimumab therapy,18,21-24 although not all evi-
dence supports this hypothesis.25 One recent retrospective analysis
found that neither immune-related AE development nor systemic
corticosteroid use affected OS or time to treatment failure in patients
treated with ipilimumab.26 In an analysis of nivolumab studies that
used a landmark approach, OS was greater in patients who expe-
rienced a select AE compared with those who did not, particularly for
individuals with three or more select AEs.27 In our analysis, we found
a signiﬁcantly higher ORR, but no impact on median PFS, when
a landmark analysis was used that excluded patients who experienced
progression early, in patients who experienced any-grade select AEs
compared with those who did not. Prospective validation of these
ﬁndings in future studies is required.
In conclusion, we found that treatment-related AEs with
nivolumabmonotherapy in advancedmelanomawere primarily low
grade and were not inﬂuenced by prior ipilimumab treatment. An
awareness of the typical timing of onset of immune-related select
7030200
Time to Resolution (weeks)
105 15 25 65
28.6 (0.1-68.1+)
4.4 (1.4-11.1)
3.6 (0.9-6.3)
3.3 (3.0-5.1+)
4.7 (3.3-6.1)
6.0 (1.0-8.1+)
Skin (n = 21 [48%] of 44)
GI (n = 6 [86%] of 7)
Endocrine (n = 2 [100%] of 2)
Hepatic (n = 2 [67%] of 3)
Pulmonary (n = 5 [71%] of 7)
Renal (n = 2 [100%] of 2)
Fig 4. Time to resolution of treatment-
related select adverse events (AEs) of any
grade with immune-modulating agents.
Circles represent medians, and bars in-
dicate ranges (values shown above bars).
Number and percent indicate patients
whose AEs resolved. The symbols “+” in
ranges and “¤” on bars indicate censored
values. Grade 3 to 4 eventswere as follows:
in two patients with skin AEs, median time
to resolution was not reached (range, 2.6 to
48.6+ weeks); in ﬁve patients with GI AEs,
median time to resolution was 1.4 weeks
(range, 0.6 to 3 weeks); in two patients with
endocrine AEs, median time to resolution
was 3.6 weeks (range, 0.9 to 6.3 weeks);
in two patients with hepatic AEs, median
time to resolution was 2.7 weeks (range,
2.0 to 3.3 weeks); and in two patients with
renal AEs, median time to resolution was
4.7 weeks (range, 3.3 to 6.1 weeks).
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AEs may aid in their early recognition and management in clinical
practice. However, because these data were from clinical trials ex-
cluding patients with autoimmune disease, organ dysfunction, and
active brain metastases, safety in these contexts requires further
study. Importantly, almost all grade 3 to 4 select AEs resolved using
nivolumab safety management guidelines, and use of systemic IMs
to manage high-grade AEs did not seem to have an impact on
antitumor beneﬁt.
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Appendix
Table A1. Baseline Characteristics of Patients Receiving Nivolumab
Monotherapy (N = 576)
Characteristic Percentage of Patients
Age, years
Median 61
Range 18-89
$ 65 37.8
$ 75 13.2
Sex
Male 60.6
Female 39.4
ECOG performance status
0 63.5
1 35.6
2 0
Not reported 0.9
LDH . ULN 43.4
M stage at study entry
M0 5.6
M1A 9.4
M1B 17.0
M1C 64.1
Not reported 4.0
Brain metastasis 11.6
BRAF status
Mutant 14.2
Wild type 81.1
Not reported 4.7
PD-L1 expression $ 5%
Yes 25.7
No or indeterminate 39.6
Not evaluable or unknown 19.4
Not reported 15.3
Previous therapy
Chemotherapy 33.2
Immunotherapy 64.4
Ipilimumab 54.2
Radiotherapy 38.4
Surgery 99.3
No. of nivolumab doses
Median 9
Range 1-61
Treatment duration, months
Median 3.7
Range 0.0-21.7
Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lactate
dehydrogenase; M, metastasis; PD-L1, programmed death ligand-1; ULN, upper
limit of normal.
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Table A2. Demographic Characteristics of Patients Receiving Nivolumab Monotherapy on the Basis of Development of Treatment-Related Select AEs (N = 576)
Characteristic
Percentage of Patients
Any Treatment-Related Select AEs (n = 255) No Treatment-Related Select AEs (n = 321)
Age, years
Median 62 59
Range 21-86 18-89
Sex
Male 59.2 61.7
Female 40.8 38.3
ECOG performance status
0 63.9 63.2
1 35.7 35.5
LDH . ULN 38.0 47.7
M stage at study entry
M0 7.5 4.0
M1A 10.6 8.4
M1B 16.1 17.8
M1C 61.6 66.0
Brain metastasis 7.8 14.6
BRAF status
Mutant 9.8 17.8
Wild type 85.5 77.6
PD-L1 expression $ 5%
Yes 28.2 23.7
No or indeterminate 42.0 37.7
Not evaluable or unknown 19.6 19.3
Not reported 10.2 19.3
Previous therapy
Chemotherapy 29.0 36.4
Immunotherapy 60.4 67.6
Radiotherapy 32.2 43.3
Surgery 98.8 99.7
No. of nivolumab doses
Median 13 7
Range 1-61 1-35
Treatment duration, months
Median 6.0 2.8
Range 0-22 0-16
Abbreviations: AE, adverse event; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; M, metastasis; PD-L1, programmed death ligand-1;
ULN, upper limit of normal.
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Table A3. Treatment-Related AEs Occurring in $ 1% of Patients* Receiving Nivolumab Monotherapy (N = 576)
AE Term
No. of Patients Reporting AEs (%)
Any Grade Grade 3 to 4
Any AE 409 (71.0) 57 (9.9)
General disorders and administration site conditions 218 (37.8) 3 (0.5)
Fatigue 143 (24.8) 2 (0.3)
Asthenia 39 (6.8) 0
Pyrexia 28 (4.9) 0
Chills 12 (2.1) 0
Edema peripheral 10 (1.7) 1 (0.2)
Inﬂuenza-like illness 8 (1.4) 0
Skin and subcutaneous tissue disorders 215 (37.3) 4 (0.7)
Pruritus 99 (17.2) 1 (0.2)
Rash 73 (12.7) 2 (0.3)
Vitiligo 45 (7.8) 0
Rash maculopapular 26 (4.5) 1 (0.2)
Dry skin 24 (4.2) 0
Erythema 14 (2.4) 0
Alopecia 8 (1.4) 0
Photosensitivity reaction 8 (1.4) 0
Eczema 7 (1.2) 0
Rash papular 7 (1.2) 0
GI disorders 175 (30.4) 11 (1.9)
Diarrhea 73 (12.7) 3 (0.5)
Nausea 69 (12.0) 0
Constipation 32 (5.6) 0
Vomiting 26 (4.5) 2 (0.3)
Abdominal pain 20 (3.5) 1 (0.2)
Dry mouth 15 (2.6) 0
Colitis 6 (1.0) 4 (0.7)
Musculoskeletal and connective tissue disorders 77 (13.4) 3 (0.5)
Arthralgia 39 (6.8) 0
Myalgia 23 (4.0) 0
Pain in extremity 11 (1.9) 0
Investigations 69 (12.0) 14 (2.4)
AST increased 16 (2.8) 2 (0.3)
Weight decreased 14 (2.4) 0
ALT increased 11 (1.9) 4 (0.7)
Lipase increased 10 (1.7) 6 (1.0)
Lymphocyte count decreased 7 (1.2) 1 (0.2)
Nervous system disorders 61 (10.6) 5 (0.9)
Headache 22 (3.8) 0
Dysgeusia 12 (2.1) 0
Dizziness 7 (1.2) 1 (0.2)
Metabolism and nutrition disorders 45 (7.8) 5 (0.9)
Decreased appetite 30 (5.2) 0
Hyperglycemia 6 (1.0) 4 (0.7)
Endocrine disorders 42 (7.3) 2 (0.3)
Hypothyroidism 30 (5.2) 0
Hyperthyroidism 15 (2.6) 1 (0.2)
Blood and lymphatic system disorders 39 (6.8) 7 (1.2)
Anemia 25 (4.3) 3 (0.5)
Lymphopenia 12 (2.1) 3 (0.5)
Respiratory, thoracic and mediastinal disorders 38 (6.6) 0
Cough 15 (2.6) 0
Dyspnea 13 (2.3) 0
Pneumonitis 10 (1.7) 0
Eye disorders 26 (4.5) 1 (0.2)
Vision blurred 6 (1.0) 0
Injury, poisoning, and procedural complications 22 (3.8) 1 (0.2)
Infusion-related reaction 18 (3.1) 1 (0.2)
Infections and infestations 21 (3.6) 2 (0.3)
Nasopharyngitis 6 (1.0) 0
Vascular disorders 19 (3.3) 2 (0.3)
Hot ﬂush 6 (1.0) 0
Ear and labyrinth disorders 11 (1.9) 0
Cardiac disorders 10 (1.7) 1 (0.2)
Renal and urinary disorders 10 (1.7) 2 (0.3)
(continued on following page)
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Table A3. Treatment-Related AEs Occurring in $ 1% of Patients* Receiving Nivolumab Monotherapy (N = 576) (continued)
AE Term
No. of Patients Reporting AEs (%)
Any Grade Grade 3 to 4
Immune system disorders 9 (1.6) 0
Hypersensitivity 9 (1.6) 0
Psychiatric disorders 9 (1.6) 0
Reproductive system and breast disorders 7 (1.2) 0
Abbreviation: AE, adverse event.
*Among events occurring in , 1% of patients, notable events included one instance each of grade 3 to 4 pancreatitis, autoimmune neuropathy, demyelination,
Guillain-Barre´ syndrome, involuntary muscle contractions, and uveitis.
Table A4. All-Cause AEs Occurring in $ 5% of Patients Receiving Nivolumab
Monotherapy (N = 576)
AE Term
No. of Patients Reporting AEs (%)
Any Grade Grade 3 to 4 Grade 5
Total patients with an event 549 (95.3) 201 (34.9) 30 (5.2)
Fatigue 229 (39.8) 8 (1.4) 0
Diarrhea 141 (24.5) 7 (1.2) 0
Nausea 138 (24.0) 3 (0.5) 0
Pruritus 125 (21.7) 1 (0.2) 0
Constipation 109 (18.9) 2 (0.3) 0
Rash 103 (17.9) 2 (0.3) 0
Decreased appetite 97 (16.8) 1 (0.2) 0
Cough 93 (16.1) 0 0
Pyrexia 82 (14.2) 2 (0.3) 0
Headache 81 (14.1) 3 (0.5) 0
Arthralgia 78 (13.5) 0 0
Anemia 76 (13.2) 19 (3.3) 0
Vomiting 73 (12.7) 7 (1.2) 0
Dyspnea 69 (12.0) 6 (1.0) 0
Back pain 68 (11.8) 8 (1.4) 0
Asthenia 66 (11.5) 4 (0.7) 0
Abdominal pain 60 (10.4) 11 (1.9) 0
Edema peripheral 58 (10.1) 5 (0.9) 0
Pain in extremity 55 (9.5) 4 (0.7) 0
Pain 50 (8.7) 7 (1.2) 0
Vitiligo 47 (8.2) 0 0
Insomnia 46 (8.0) 1 (0.2) 0
Musculoskeletal pain 45 (7.8) 1 (0.2) 0
Dizziness 45 (7.8) 1 (0.2) 0
Nasopharyngitis 44 (7.6) 0 0
Malignant neoplasm progression 44 (7.6) 19 (3.3) 22 (3.8)
Dry skin 40 (6.9) 0 0
Hypothyroidism 40 (6.9) 0 0
AST increased 39 (6.8) 10 (1.7) 0
Myalgia 38 (6.6) 0 0
Weight decreased 37 (6.4) 0 0
ALT increased 30 (5.2) 11 (1.9) 0
Anxiety 29 (5.0) 1 (0.2) 0
Hypertension 29 (5.0) 6 (1.0) 0
Abbreviation: AE, adverse event.
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Table A5. Immunomodulatory Agents Used for Management of AEs in
Patients Receiving Nivolumab in Phase III Trials (n = 474)
Medication No. of Patients (%)
Any immune-modulating agent 166 (35.0)
Corticosteroid, systemic 114 (24.1)
Prednisone 43 (9.1)
Dexamethasone 39 (8.2)
Methylprednisolone 33 (7.0)
Hydrocortisone 16 (3.4)
Prednisolone 16 (3.4)
Meprednisone 5 (1.1)
Betamethasone 4 (0.8)
Corticosteroid 2 (0.4)
Fludrocortisone 1 (0.2)
Triamcinolone 1 (0.2)
Corticosteroid, dermatologic preparation 76 (16.0)
Betamethasone, topical 22 (4.6)
Hydrocortisone, topical 21 (4.4)
Triamcinolone, topical 13 (2.7)
Mometasone 8 (1.7)
Clobetasol 6 (1.3)
Methylprednisolone, topical 4 (0.8)
Prednicarbate 4 (0.8)
Desonide 3 (0.6)
Dexamethasone, topical 3 (0.6)
Diﬂucortolone 3 (0.6)
Betamethasone/calcipotriene 2 (0.4)
Betamethasone/fusidic acid 2 (0.4)
Betamethasone/salicylic acid 2 (0.4)
Budesonide, topical 2 (0.4)
Prednisolone, topical 2 (0.4)
Ciptop/hctop 1 (0.2)
Clioquinol/ﬂumethasone 1 (0.2)
Flumethasone/triamcinolone 1 (0.2)
Fluocortolone, topical 1 (0.2)
Fluticasone, topical 1 (0.2)
Prednisone, topical 1 (0.2)
Corticosteroid, inhaled 5 (1.1)
Budesonide/formoterol 3 (0.6)
Beclomethasone 1 (0.2)
Beclomethasone inhaler 1 (0.2)
Nonsteroidal systemic immunosuppressive agents 3 (0.6)
Inﬂiximab 2 (0.4)
Mycophenolic acid 1 (0.2)
Immunoglobulin 1 (0.2)
Gamma globulin 1 (0.2)
Abbreviation: AE, adverse event.
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Fig A1. Kaplan-Meier plot of PFS in (A) patients with 0, 1-2, or 3+ treatment-related select AEs and (B) patients with all grade treatment-related select AEs, grade 3-4
treatment-related select AEs, and all patients. The symbols “+,” “s,” and “à” indicate censored points. AE, adverse event; NA, not assessable; PFS, progression-free
survival.
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